Atsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, Meghan R Tedesco, David Gibson, Payal B Watchmaker, Kaori Okada, Albert S Wang, Anny Shai, Andres M Salazar, Annette M Molinaro, Jane E Rabbitt, Maryam Shahin, Arie Perry, Jennifer L Clarke, Jennie W Taylor, Mariza Daras, Nancy Ann Oberheim Bush, Shawn L Hervey-Jumper, Joanna J Phillips, Susan M Chang, Norbert Hilf, Andrea Mayer-Mokler, Tibor Keler, Mitchel S Berger, Hideho Okada
BACKGROUND: Central nervous system (CNS) WHO grade 2 low-grade glioma (LGG) patients are at high risk for recurrence and with unfavorable long-term prognosis due to the treatment resistance and malignant transformation to high-grade glioma. Considering the relatively intact systemic immunity and slow-growing nature, immunotherapy may offer an effective treatment option for LGG patients. METHODS: We conducted a prospective, randomized pilot study to evaluate the safety and immunological response of the multipeptide IMA950 vaccine with agonistic anti-CD27 antibody, varlilumab, in CNS WHO grade 2 LGG patients...
February 2, 2024: Neuro-oncology